Mozobil (plerixafor injection) is approved by the United States Food and Drug Administration (FDA) to be used with another agent, granulocyte-colony stimulating factor (G-CSF), to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
The safety and efficacy of Mozobil in children has not been established in clinical studies.
Mozobil releases hematopoietic stem cells from the bone marrow into the bloodstream by disrupting a bond that normally keeps stem cells anchored to the bone marrow. This enables your healthcare team to collect more stem cells during apheresis.
Benefits of Mozobil
Clinical studies demonstrated that using Mozobil with G-CSF, had several benefits as compared to using G-CSF alone for the mobilization of stem cells in patients with NHL or MM.
Patients taking Mozobil may experience certain side effects. The most common side effects (adverse reactions), occurring in greater than 10% of patients during HSC mobilization were: diarrhea, nausea, tiredness (fatigue), injection site reaction, headache, pain in your joints (arthralgia), dizziness and vomiting.